Literature DB >> 32376555

[Effect of cyclophosphamide on hematopoietic stem cells in mice with iron overload].

Yanjun Xu1,2, Tiantian Yi1, Xiaoxiao Xu1, Fuyu Pei1, Yuelin He1, Xuedong Wu1.   

Abstract

OBJECTIVE: To explore the effect of cyclophosphamide on hematopoietic stem cells (HSCs) in mice with iron overload.
METHODS: Mouse models of iron overload were established in 30 male C57BL/6 mice by intraperitoneal injections of iron dextran at low (0.25 g/kg), moderate (0.5 g/kg), and high (1 g/kg) doses (n=10), with another 10 PBS-treated mice as the control group. The changes in body weight, liver, spleen and bone marrow of the mice were recorded, and serum level of ferritin was detected. The mice receiving a moderate dose of iron dextran were further divided into 8 groups for observation at different time points (D1, D2, D3, D4, D5, D6, D7, and D14 groups) and were given intraperitoneal injection of 50 mg/kg cyclophosphamide (Cy) for 2 consecutive days. Peripheral blood cells, bone marrow mononuclear cells (BMMNCs), and the frequencies of different HSCs (HPCs, HSCs, LT-HSCs) in the BMMNCs were monitored. The cell cycle distribution in the HSCs, level of reactive oxygen species and the microenvironment of the HSCs were analyzed using flow cytometry.
RESULTS: Compared with the control mice, the mice with iron overload showed obvious weight loss with significantly increased serum ferritin level, enlargement of the liver and spleen, and iron deposition in the organs (P < 0.05). No significant changes were noted in the peripheral blood of the mice with iron overload. The cyclophosphamide-treated mice exhibited significantly decreased number of WBCs and lymphocyte ratio at days 1 to 4 (P < 0.05). The numbers of BMMNCs and HPCs in mice with iron overload did not show significant changes as compared with those in the control mice, but the numbers of HSCs and LTHSCs decreased significantly in the mice with iron overload (P < 0.05). In cyclophosphamide-treated mice, the number of HSCs increased since day 1 and reached the peak level on day 3 (P < 0.05). Compared with those in the control group, the HSCs did not exhibit significant changes in cell cycle distribution in mice with iron overload, but the proportion of G0/G1 cells decreased significantly in cyclophosphamide group since day 1 and reached the lowest level on day 3 (P < 0.05).
CONCLUSIONS: Iron deposition in the bone marrow causes long- term damages of the HSCs in the bone marrow but does not induce obvious changes in the peripheral blood. In mice with iron overload, intraperitoneal injection of 50 mg/kg cyclophosphamide for two days promotes cell cycle changes of the resting HSCs to mobilize the HSCs, and this effect is the most obvious on day 4.

Entities:  

Keywords:  animal model; cyclophosphamide; hematopoietic stem cells; iron overload

Mesh:

Substances:

Year:  2020        PMID: 32376555      PMCID: PMC7040758          DOI: 10.12122/j.issn.1673-4254.2020.01.18

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  27 in total

1.  Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.

Authors:  Usanarat Anurathapan; Samart Pakakasama; Pimsiri Mekjaruskul; Nongnuch Sirachainan; Duantida Songdej; Ampaiwan Chuansumrit; Pimlak Charoenkwan; Arunee Jetsrisuparb; Kleebsabai Sanpakit; Bunchoo Pongtanakul; Piya Rujkijyanont; Arunotai Meekaewkunchorn; Rosarin Sruamsiri; Artit Ungkanont; Surapol Issaragrisil; Borje S Andersson; Suradej Hongeng
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-23       Impact factor: 5.742

2.  Circulating stem cells in mice treated with cyclophosphamide.

Authors:  C F Craddock; J F Apperley; E G Wright; L E Healy; C A Bennett; M Evans; P G Grimsley; M Y Gordon
Journal:  Blood       Date:  1992-07-01       Impact factor: 22.113

3.  Evaluation of hepatic iron overload in Chinese children with β-thalassemia major.

Authors:  Lu-Hong Xu; Jian-Pei Fang; Hong-Gui Xu; Wen-Jun Weng
Journal:  Pediatr Hematol Oncol       Date:  2011-10-04       Impact factor: 1.969

4.  Bone loss caused by iron overload in a murine model: importance of oxidative stress.

Authors:  Jaime Tsay; Zheiwei Yang; F Patrick Ross; Susanna Cunningham-Rundles; Hong Lin; Rhima Coleman; Philipp Mayer-Kuckuk; Stephen B Doty; Robert W Grady; Patricia J Giardina; Adele L Boskey; Maria G Vogiatzi
Journal:  Blood       Date:  2010-06-16       Impact factor: 22.113

5.  Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

Authors:  Je-Hwan Lee; Young-Don Joo; Hawk Kim; Hun Mo Ryoo; Min Kyoung Kim; Gyeong-Won Lee; Jung-Hee Lee; Won-Sik Lee; Jae-Hoo Park; Sung-Hwa Bae; Myung Soo Hyun; Dae-Young Kim; Sung-Doo Kim; Young Joo Min; Kyoo-Hyung Lee
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

6.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

Authors:  Edward A Copelan; Betty K Hamilton; Belinda Avalos; Kwang Woo Ahn; Brian J Bolwell; Xiaochun Zhu; Mahmoud Aljurf; Koen van Besien; Christopher Bredeson; Jean-Yves Cahn; Luciano J Costa; Marcos de Lima; Robert Peter Gale; Gregory A Hale; Joerg Halter; Mehdi Hamadani; Yoshihiro Inamoto; Rammurti T Kamble; Mark R Litzow; Alison W Loren; David I Marks; Eduardo Olavarria; Vivek Roy; Mitchell Sabloff; Bipin N Savani; Matthew Seftel; Harry C Schouten; Celalettin Ustun; Edmund K Waller; Daniel J Weisdorf; Baldeep Wirk; Mary M Horowitz; Mukta Arora; Jeff Szer; Jorge Cortes; Matt E Kalaycio; Richard T Maziarz; Wael Saber
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

7.  Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control.

Authors:  Usanarat Anurathapan; Samart Pakakasama; Piya Rujkijyanont; Nongnuch Sirachainan; Duantida Songdej; Ampaiwan Chuansumrit; Somtawin Sirireung; Pimlak Charoenkwan; Arunee Jetsrisuparb; Surapol Issaragrisil; Artit Ungkanont; Rosarin Sruamsiri; Supanart Srisala; Borje S Andersson; Suradej Hongeng
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-03       Impact factor: 5.742

8.  The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice.

Authors:  Marco Musumeci; Sonia Maccari; Paola Sestili; Alessia Massimi; Elisa Corritore; Giuseppe Marano; Liviana Catalano
Journal:  Blood Transfus       Date:  2012-06-28       Impact factor: 3.443

9.  Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin.

Authors:  Bo-Kyoung Park; Hyo-Sup Kim; Seongkoo Kim; Jae-Wook Lee; Young Shil Park; Pil-Sang Jang; Nack-Gyun Chung; Dae-Chul Jeong; Bin Cho
Journal:  Blood Res       Date:  2018-06-25

10.  Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity.

Authors:  Stefania Crippa; Valeria Rossella; Annamaria Aprile; Laura Silvestri; Silvia Rivis; Samantha Scaramuzza; Stefania Pirroni; Maria Antonietta Avanzini; Luca Basso-Ricci; Raisa Jofra Hernandez; Marco Zecca; Sarah Marktel; Fabio Ciceri; Alessandro Aiuti; Giuliana Ferrari; Maria Ester Bernardo
Journal:  J Clin Invest       Date:  2019-02-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.